☆ 4.5 Review

Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment

CURRENT ONCOLOGY REPORTS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma

Ho-Man Yeung et al.

Summary: This study aims to evaluate the outcomes of second-line therapies for treating EP-NEC after first-line platinum-based chemotherapy. The results show that second-line therapies containing irinotecan/topotecan are not significantly different from other agents in terms of overall survival and progression-free survival, regardless of the primary site.

JOURNAL OF GASTROINTESTINAL CANCER (2023)

Add to Collection

News Item Gastroenterology & Hepatology

Futibatinib for intrahepatic cholangiocarcinoma

Holly Baker

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Add to Collection

Article Oncology

Genetic alterations of GI-NECs involving three main signaling pathways

Qiong Dai et al.

Summary: This study aims to provide additional data about genomic characteristics of gastrointestinal neuroendocrine neoplasms (GI-NENs) and the genetic differences between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). The study found that genetic alterations were very common in NECs, while rare in NETs. NECs had significantly higher tumor mutational burden (TMB) compared to NETs. These genetic alterations frequently involved DNA repair and cell cycle, PI3K/AKT/mTOR, and TGF-beta/SMAD4 signaling pathways.

CANCER MEDICINE (2023)

Add to Collection

Article Endocrinology & Metabolism

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma

Halfdan Sorbye et al.

Summary: This ENETS guidance paper provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma. It emphasizes the importance of surgical intervention for localized disease and recommends specific treatment options for metastatic disease. The paper also highlights the need for more prospective clinical trials to address the unmet needs in this field and improve the survival of patients with advanced disease.

JOURNAL OF NEUROENDOCRINOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas

Jennifer J. Gile et al.

Summary: Poorly differentiated extrapulmonary neuroendocrine carcinomas (EP NECs) are aggressive cancers. EP NECs are typically treated with platinum-based regimens, and some clinicians have added a checkpoint inhibitor (CPI) to the treatment based on data from trials in patients with small cell carcinoma of the lung. However, a retrospective study did not find any additional benefit of adding CPI to the standard chemotherapy in EP NECs.

JOURNAL OF NEUROENDOCRINOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms

Hege Elvebakken et al.

Summary: High-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN) have early dissemination and limited treatment benefit for metastatic disease. Mutations in HG GEP-NEN are associated with different clinical outcomes. Reliable biomarkers are needed to predict treatment outcome and prognosis. KRAS and BRAF mutations, as well as microsatellite instability (MSI), were analyzed in metastatic HG GEP-NEN cases. MUTATION RESULTS: Higher frequency of mutations in NEC compared to NET G3, with colon NEC showing a high frequency of BRAF mutations. BRAF mutation in colon NEC predicted immediate disease progression on first-line chemotherapy. KRAS mutation was associated with inferior overall survival in NEC, but not for those receiving first-line chemotherapy. Both KRAS and BRAF mutations had different clinical impacts compared to digestive adenocarcinoma.

JOURNAL OF NEUROENDOCRINOLOGY (2023)

Add to Collection

Article Oncology

Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma

Stian Knappskog et al.

JCO Precision Oncology (2023)

Add to Collection

Article Oncology

Bevacizumab plus FOLFIRI after failure of platinum- etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC) : a randomised, multicentre, non-comparative, open-label, phase 2 trial

Thomas Walter et al.

Summary: This study evaluates the efficacy of FOLFIRI plus bevacizumab and FOLFIRI alone as second-line treatment for gastroenteropancreatic neuroendocrine carcinoma. The addition of bevacizumab did not seem to improve overall survival compared to FOLFIRI alone, suggesting that FOLFIRI could be considered as the standard second-line treatment for this type of cancer.

LANCET ONCOLOGY (2023)

Add to Collection

Review Oncology

Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma

Melissa Frizziero et al.

Summary: Poorly differentiated neuroendocrine carcinomas (PD-NEC) are rare cancers that have gained attention due to improved diagnostic methods and the phenomenon of NE lineage plasticity. However, effective treatment options for PD-NEC patients are challenging due to the lack of targetable molecular drivers, limited preclinical models, and validated biomarkers.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms

Andreas Venizelos et al.

Summary: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are a rare and understudied type of tumors, with a very poor prognosis. Molecular analysis of 181 HG GEP-NEN patients revealed unique genetic alterations and copy number changes in different subgroups of tumors, indicating potential personalized treatment options. Limited similarities were found with small-cell lung cancer (SCLC), suggesting the need for subtype-specific therapeutic approaches.

ENDOCRINE-RELATED CANCER (2022)

Add to Collection

Article Oncology

Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System

Shinichi Yachida et al.

Summary: Gastrointestinal neuroendocrine carcinoma (GIS-NEC) is a rare but highly malignant tumor that is genetically distinct from gastrointestinal neuroendocrine tumors (GIS-NET). There are clear genomic differences between pancreatic NECs (Pant-NEC) and nonpancreatic GIS-NECs (Nonpanc-NEC). Panc-NECs can be classified into two subgroups based on genomic and epigenomic features.

CANCER DISCOVERY (2022)

Add to Collection

Article Oncology

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms

T. Al-Toubah et al.

Summary: The combination therapy of ipilimumab and nivolumab shows modest activity in patients with high-grade neuroendocrine neoplasms who have progressed on prior cytotoxic chemotherapy.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)

Amr Mohamed et al.

Summary: This study retrospectively analyzed the treatment outcomes of EP-NEC patients and found that dual ICPIs showed better progression-free survival and overall survival in patients with EP-NEC in the second-line setting, compared to single ICPIs or cytotoxic chemotherapy.

CANCERS (2022)

Add to Collection

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

L. Paz-Ares et al.

Summary: In extensive-stage small-cell lung cancer (ES-SCLC), durvalumab plus EP continues to improve overall survival (OS), while durvalumab plus tremelimumab plus EP shows numerical improvement but does not reach statistical significance.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials

D. L. Chan et al.

Summary: Single-agent PD-L1 blockade with avelumab demonstrated limited antitumor activity in patients with G2-3 NENs. Further studies are needed to explore the role of dual immunotherapy and other combination treatments in this population.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

Mairead Geraldine McNamara et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.

Jennifer Rachel Eads et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

David Bing Zhen et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin

M. C. Riesco Martinez et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study

Julien Hadoux et al.

Summary: This study reports the results of second-line chemotherapy with etoposide based rechallenge (EBR) in neuroendocrine carcinoma (NEC) patients. It also investigates the prognostic role of RB1 status in this context. The study found that RB1 status does not affect prognosis in NEC patients receiving second-line chemotherapy. However, EBR may be the best option for patients with an initial response to first-line platinum-etoposide chemotherapy lasting at least 3 months.

ENDOCRINE-RELATED CANCER (2022)

Add to Collection

Article Oncology

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study

Federico Longo-Munoz et al.

Summary: This study evaluated the efficacy and safety of lurbinectedin in patients with neuroendocrine tumors. The results showed that lurbinectedin had some antitumor activity in certain patients and had an acceptable and manageable safety profile. This study suggests further development of lurbinectedin in a more selected population of patients is warranted.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System The TOPIC-NEC Phase 3 Randomized Clinical Trial

Chigusa Morizane et al.

Summary: This study aimed to compare the efficacy of EP and IP in terms of overall survival (OS) in patients with NEC of the digestive system. The results showed no significant difference in OS between EP and IP, but EP had better outcomes in patients with poorly differentiated NEC of pancreatic origin. Adverse events were more common in the EP group.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites

Thomas Yang Sun et al.

Summary: High-grade (grade 3) neuroendocrine neoplasms (G3 NENs) have poor survival outcomes. In this study, whole transcriptome, whole exome, and gene copy number sequencing were performed on G3 NEN samples from diverse organs. The study found that G3 NENs did not have gene expression profiles that were easily segregated by organ of origin. Mutations in TP53, APC, RB1, and CDKN2A were found across all G3 NENs. The CDK4/6 cell cycling pathway was mutated in 95% of cases, and oncogenes within this pathway were upregulated. G3 NENs had a high tumor mutation burden and somatic copy number alterations were associated with worse prognosis.

ENDOCRINE-RELATED CANCER (2022)

Add to Collection

Review Oncology

Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis

Akihiro Ohmoto et al.

Summary: This study conducted a systematic review and meta-analysis to evaluate the efficacy of platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma. The results showed considerable response rate and survival time when using the platinum-doublet regimen. The IP and EP regimens were found to be reasonably applicable.

DISCOVER ONCOLOGY (2022)

Add to Collection

Article Oncology

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System The TOPIC-NEC Phase 3 Randomized Clinical Trial

Chigusa Morizane et al.

Summary: The results of this randomized clinical trial indicate that both EP and IP are still the standard first-line chemotherapy options, although grade 3 and 4 adverse events were more common in the EP arm.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma

Noritoshi Kobayashi et al.

Summary: Temozolomide monotherapy is a feasible, modestly effective, and safe treatment for patients with unresectable EPNEC following platinum-based chemotherapy, especially those with MGMT deficiency.

CANCER SCIENCE (2021)

Add to Collection

Article Oncology

Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

James C. Yao et al.

Summary: Spartalizumab, a humanized anti-PD-1 monoclonal antibody, showed limited efficacy in patients with well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. However, there were promising results in the thoracic cohort, indicating the need for further investigation. The most common adverse events related to spartalizumab were fatigue and nausea in the NET group, and elevated liver enzymes in the GEP-NEC group.

ENDOCRINE-RELATED CANCER (2021)

Add to Collection

Article Oncology

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero et al.

Summary: The study evaluated different treatment regimens for patients with BRAF V600E-mutant metastatic colorectal cancer, showing that encorafenib plus cetuximab improved overall survival, objective response rate, and progression-free survival compared to standard chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review

Tiziana Feola et al.

Summary: NECs are heterogeneous tumors that can be further divided into two prognostically distinct categories based on the Ki67 LI < 55%. Those with lower Ki67 LI have a better prognosis and should be treated and monitored differently from those with higher Ki67 LI.

CANCERS (2021)

Add to Collection

Article Oncology

SWOG S1609-A phase 2 basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors: A high-grade neuroendocrine neoplasm cohort

Sandip Pravin Patel et al.

Summary: In this study, the combination therapy of ipilimumab plus nivolumab showed a 26% overall response rate in patients with high-grade neuroendocrine neoplasms, with low toxicity. The results suggest that this treatment produces durable responses in patients with refractory disease.

CANCER (2021)

Add to Collection

Article Gastroenterology & Hepatology

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin

Julien Hadoux et al.

Summary: This study aims to compare the survival and quality of life of patients with neuroendocrine carcinoma under different chemotherapy regimens through a randomized allocation of 218 patients. Recruitment started on October 20, 2020 and the study is ongoing.

DIGESTIVE AND LIVER DISEASE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms Mayo Clinic Experience

Jennifer J. Gile et al.

Summary: Overall, the study found that checkpoint inhibitor therapy had limited efficacy in patients with NENs. Poorly differentiated NECs had varying response rates and progression-free survival times on different CPI therapies, while well-differentiated NETs showed mixed responses. Future research should focus on identifying biomarkers to predict patient responses to immunotherapy.

PANCREAS (2021)

Add to Collection

Meeting Abstract Oncology

Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

N. Girard et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors

Leigh Marcus et al.

Summary: The FDA approved pembrolizumab for the treatment of TMB-H solid tumors in adults and children, based on its significant overall response rate and duration in clinical trials. This marks the first FDA approval of a cancer treatment based on TMB, and the fourth based on a biomarker rather than primary site.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Meeting Abstract Oncology

Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.

Lin Shen et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review

David L. Chan et al.

Summary: The study evaluated the clinical efficacy of TEM-containing regimens in advanced grade 3 gastroenteropancreatic neuroendocrine neoplasms, showing a 36% radiographic response rate and median TTF and OS of 3.6 and 19.2 months respectively. CAPTEM was considered a viable treatment option in managing G3 NENs based on the study results.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

Jaume Capdevila et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip P. Patel et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Ming Lu et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Review Oncology

PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Halfdan Sorbye et al.

ENDOCRINE-RELATED CANCER (2020)

Add to Collection

Article Endocrinology & Metabolism

A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial)

Hiroyuki Okuyama et al.

NEUROENDOCRINOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms

Stefan Munker et al.

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2020)

Add to Collection

Article Oncology

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

Namrata Vijayvergia et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study

Panpan Zhang et al.

CANCER (2020)

Add to Collection

Article

Blood-based next-generation sequencing analysis of neuroendocrine neoplasms

Katerina Zakka et al.

Oncotarget (2020)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma

Patrick W. McGarrah et al.

PANCREAS (2020)

Add to Collection

Article Oncology

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

Alberto Puccini et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol

Alberto Bongiovanni et al.

BMJ OPEN (2020)

Add to Collection

Review Oncology

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis

Mairead G. McNamara et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

Jingjing Zhang et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

Add to Collection

Article Oncology

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

Esben Andreas Carlsen et al.

ENDOCRINE-RELATED CANCER (2019)

Add to Collection

Meeting Abstract Oncology

Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).

Claire Mulvey et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).

Christian Fottner et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.

Nataliya Volodymyrivna Uboha et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

1400PEfficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma

L Apostolidis et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Endocrinology & Metabolism

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms

Anna Pellat et al.

NEUROENDOCRINOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases

Arvind Dasari et al.

CANCER (2018)

Add to Collection

Article Oncology

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

T. Walter et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma

Norimitsu Kasahara et al.

MOLECULAR AND CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

P1-3-4Amrubicin therapy for platinum-refractory extrapulmonary neuroendocrine carcinoma: Retrospective single-center analysis

Yukako Hattori et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Meeting Abstract Oncology

Efficacy of amrubicin monotherapy after platinum chemotherapy for non-gastrointestinal extrapulmonary neuroendocrine carcinoma

T. Ebata et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Oncology

Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract

Tomonori Araki et al.

ANTI-CANCER DRUGS (2016)

Add to Collection

Review Oncology

Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement

Romain Coriat et al.

ONCOLOGIST (2016)

Add to Collection

Article Oncology

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy

Samuel J. Klempner et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Oncology

Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma

Leonidas Apostolidis et al.

CANCER MEDICINE (2016)

Add to Collection

Meeting Abstract Oncology

Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites

Emily K. Bergsland et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Pathology

The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms

Olca Basturk et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)

Add to Collection

Article Oncology

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma

J. Hadoux et al.

ENDOCRINE-RELATED CANCER (2015)

Add to Collection

Article Oncology

Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms

M. Heetfeld et al.

ENDOCRINE-RELATED CANCER (2015)

Add to Collection

Article Oncology

A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum

James D. Smith et al.

ANNALS OF SURGICAL ONCOLOGY (2014)

Add to Collection

Article Oncology

Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system

Tomohiro Yamaguchi et al.

CANCER SCIENCE (2014)

Add to Collection

Article Oncology

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas

Ingrid Holst Olsen et al.

JOURNAL OF CANCER (2014)

Add to Collection

Article Oncology

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

H. Sorbye et al.

ANNALS OF ONCOLOGY (2013)

Add to Collection

Article Oncology

FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3

O. Hentic et al.

ENDOCRINE-RELATED CANCER (2012)

Add to Collection

Article Oncology

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

Antonio Rossi et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Multidisciplinary Sciences

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

Ingrid H. Olsen et al.

SCIENTIFIC WORLD JOURNAL (2012)

Add to Collection

Article Oncology

Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma After Progression on First-Line Chemotherapy

Staffan Welin et al.

CANCER (2011)

Add to Collection

Article Oncology

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

Guenter Kloeppel

ENDOCRINE-RELATED CANCER (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.